Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03077919 · ClinicalTrials.gov registry record · NA
Effectiveness and Acceptability of Stellate Ganglion Block for Posttraumatic Stress Disorder Symptoms - Effectiveness
A NA study, sponsored by RTI International.
- Completed
- Registry status
- NA
- Development phase
- 113
- Enrollment target
NCT03077919 is a NA study that has completed, run by RTI International. The registered enrollment target is 113 participants.
The verdict
NCT03077919, a NA study, has completed, sponsored by RTI International.
- COMPLETED
- Registry status
- NA
- Development phase
- 113 participants
- Enrollment target
Study Summary
This is a multisite, randomized, blinded, sham-procedure-controlled study to evaluate the efficacy of right-sided stellate ganglion block (SGB) on the acute symptomatology of Post traumatic Stress Disorder (PTSD), evaluated by the Clinician-Administered PTSD Scale (CAPS-5) clinical interview at pre-treatment and at 8 weeks. This entry describes the effectiveness study.The acceptability study is described in a separate entry.
Interventions
- DRUG Ropivacaine
- DRUG Sham treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2016-05-25 |
| Est. Completion | 2018-06-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03077919
The ClinicalTrials.gov registry entry for NCT03077919 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 113 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is RTI International, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ropivacaine is the first listed.
NCT03077919 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03077919 about?
NCT03077919 is a clinical study titled "Effectiveness and Acceptability of Stellate Ganglion Block for Posttraumatic Stress Disorder Symptoms - Effectiveness". This is a multisite, randomized, blinded, sham-procedure-controlled study to evaluate the efficacy of right-sided stellate ganglion block (SGB) on the acute symptomatology of Post traumatic Stress Disorder (PTSD), evaluated by the Clinician-Administered PTSD Scale (CAPS-5) clinical interview at pre-...
What is the current status of trial NCT03077919?
This trial is currently completed. It is a NA study. The enrollment target is 113 participants. The study started on 2016-05-25. Estimated completion is 2018-06-09.
What interventions are being tested in trial NCT03077919?
The interventions under investigation include: Ropivacaine (DRUG), Sham treatment (DRUG).
Who is sponsoring clinical trial NCT03077919?
This trial is sponsored by RTI International, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.